May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Effect of Topical Bevacizumab on Corneal Angiogenesis in the Rabbit Model
Author Affiliations & Notes
  • A. S. Moriyama
    Department of Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • M. N. Moraes Filho
    Department of Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • B. Furlani
    Department of Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • E. B. Rodrigues
    Department of Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • M. Maia
    Department of Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • A. B. Dias
    Department of Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • A. S. Lima
    Department of Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • F. E. Michel
    Department of Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • A. L. Hofling-Lima
    Department of Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • Footnotes
    Commercial Relationships  A.S. Moriyama, None; M.N. Moraes Filho, None; B. Furlani, None; E.B. Rodrigues, None; M. Maia, None; A.B. Dias, None; A.S. Lima, None; F.E. Michel, None; A.L. Hofling-Lima, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3744. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. S. Moriyama, M. N. Moraes Filho, B. Furlani, E. B. Rodrigues, M. Maia, A. B. Dias, A. S. Lima, F. E. Michel, A. L. Hofling-Lima; Effect of Topical Bevacizumab on Corneal Angiogenesis in the Rabbit Model. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3744. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the preventive and therapeutic effects of topical Bevacizumab on experimentally induced corneal neovascularization in a rabbit model.

Methods: : A rabbit model of suture-induced corneal neovascularization was used to assess the topical anti-angiogenic role of bevacizumab. After performing suture at day 0, animals were divided into the following groups: A: Control Group (n=4): receiving saline solution eye drops tid during 14 days beginning in the same day suture was performed. B: Therapeutic group (n=6): receiving 25mg/ml bevacizumab eye drops tid from day 14 to day 28. C: Preventive group (n=6): receiving bevacizumab 25mg/ml eye drops tid from day 0 to day 14. All the animals were evaluated and biomicroscopic photographed in the 7th (D7), 14th (D14), 21st (D21) and 28th (D28) day after the start of angiogenic stimulus with suturing. Images were morphometrically analyzed using the image processing and analysis software Image J 1.31v. (Wayne Rasband Research Services Branch, National Institute of Mental Health, Bethesda, USA). Statistical analysis was performed to compare three parameters of neovascularization regression among each of groups: area of neovascularization, radial length of the longer neovessel and limbar length of the neovascularizarion area; Student t-Test was used and values for p<0.05 were considered statistically significant.

Results: : Area of neovascularization was significantly decreased in the Preventive group at D7 (average area of 386,649 pixels in group A, 241,459 pixels in group B and 45,964 pixels in group C; p<0.05). Preventive Group had also smaller areas of neovascularization in D14, D21 and D28. Other parameters presented analogous results, in D7 radial length of the longer neovessel values (497,994 in group A, 329,266 in group B and 135,026 in group C) and limbar length of the neovascularization area (1,104 pixels in group A, 1,306 pixels in group B and 688 pixels in group C) showed decreased measures in Preventive group with statistical significance.

Conclusions: : Bevacizumab showed to be effective in minimizing neovascularization when applied early in angiogenic stimuli process, although it was ineffective in regressing neovascularization when administered later in the creased disease. These results might reflect a different action of this drug depending on the maturation degree of the corneal angiogenesis and may be clinical relevant for its use in human eyes.

Keywords: neovascularization • cornea: clinical science • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×